Selected article for: "control group and cumulative incidence"
Author: Yueping Li; Zhiwei Xie; Weiyin Lin; Weiping Cai; Chunyan Wen; Yujuan Guan; Xiaoneng Mo; Jian Wang; Yaping Wang; Ping Peng; Xudan Chen; Wenxin Hong; Guangming Xiao; Jinxin Liu; Lieguang Zhang; Fengyu Hu; Feng Li; Feng Li; Fuchun Zhang; Xilong Deng; Linghua Li
Title: An exploratory randomized, controlled study on the efficacy and safety of lopinavir/ritonavir or arbidol treating adult patients hospitalized with mild/moderate COVID-19 (ELACOI)
  • Document date: 2020_3_23
    • ID: 9hknw4ws_34
    Snippet: The author/funder, who has granted medRxiv a license to display the preprint in perpetuity. in the LPV/r group, the arbidol group and the control group, without significant statistical difference between them (P= 0.352) (table 2) . Over the 21-day follow-up, the cumulative incidence of positive-to-negative conversion of SARS-CoV-2 nucleic acid in pharyngeal swabs did not show statistical difference between the three groups ( figure 3 )......
    Document: The author/funder, who has granted medRxiv a license to display the preprint in perpetuity. in the LPV/r group, the arbidol group and the control group, without significant statistical difference between them (P= 0.352) (table 2) . Over the 21-day follow-up, the cumulative incidence of positive-to-negative conversion of SARS-CoV-2 nucleic acid in pharyngeal swabs did not show statistical difference between the three groups ( figure 3 ).

    Search related documents:
    Co phrase search for related documents
    • arbidol group and control group arbidol group: 1, 2, 3
    • arbidol group and negative positive conversion: 1, 2
    • arbidol group and nucleic acid: 1, 2, 3, 4, 5, 6, 7, 8
    • arbidol group and pharyngeal swab: 1
    • arbidol group and SARS nucleic acid: 1, 2, 3, 4, 5
    • arbidol group and SARS nucleic acid negative positive conversion: 1, 2
    • arbidol group and statistical difference: 1
    • control group and cumulative incidence: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
    • control group and negative positive conversion: 1, 2, 3, 4, 5, 6, 7
    • control group and nucleic acid: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59
    • control group and pharyngeal swab: 1, 2, 3, 4, 5, 6, 7, 8
    • control group and SARS nucleic acid: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
    • control group and SARS nucleic acid negative positive conversion: 1, 2, 3
    • control group and significant statistical difference: 1, 2, 3, 4, 5
    • control group and statistical difference: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47
    • control group arbidol group and negative positive conversion: 1, 2
    • control group arbidol group and nucleic acid: 1, 2
    • control group arbidol group and SARS nucleic acid: 1, 2
    • control group arbidol group and SARS nucleic acid negative positive conversion: 1, 2